Despite having no intrinsic enzymatic activity, Shc is an integral part of several signal transduction pathways that are found to be disrupted in various cancers. For instance, clinical studies indicate that the activation of signaling pathways involving Shc is linked with poor prognosis in patients with breast cancer [1][2][3] . Also, the receptor tyrosine kinase (RTK) Erb2, whose level of expression is inversely correlated with patient survival, must retain its Shc-binding site to efficiently transform the mammary gland 4 . Shc similarly has important roles in increasing the migratory and invasive properties of breast cancer cells [5] [6] [7] [8] [9] [10] and is involved in the regulation of angiogenesis, cell proliferation, cell survival and stress signaling during normal development. The co-option of these Shc-dependent processes by transformed cells also suggests a potential role for Shc during cancer progression 11 .
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Despite having no intrinsic enzymatic activity, Shc is an integral part of several signal transduction pathways that are found to be disrupted in various cancers. For instance, clinical studies indicate that the activation of signaling pathways involving Shc is linked with poor prognosis in patients with breast cancer [1] [2] [3] . Also, the receptor tyrosine kinase (RTK) Erb2, whose level of expression is inversely correlated with patient survival, must retain its Shc-binding site to efficiently transform the mammary gland 4 . Shc similarly has important roles in increasing the migratory and invasive properties of breast cancer cells [5] [6] [7] [8] [9] [10] and is involved in the regulation of angiogenesis, cell proliferation, cell survival and stress signaling during normal development. The co-option of these Shc-dependent processes by transformed cells also suggests a potential role for Shc during cancer progression 11 .
Of the four genes in the Shc family (shcA, shcB, shcC and shcD), only shcA is ubiquitously expressed in human cells. There are three isoforms of the ShcA protein: p46, p52 and p66. In this work, we focus on p52 ShcA (henceforth referred to simply as Shc). Structurally, Shc consists of an N-terminal phosphotyrosine-binding (PTB) domain, a collagen homology 1 (CH1) domain and a C-terminal Src homology 2 (SH2) domain, which, like the PTB domain, binds tyrosinephosphorylated proteins. The best-understood role of Shc is in linking RTKs to the mitogen-activated protein kinase (MAPK) pathway [12] [13] [14] . The canonical view of this process is that upon receptor stimulation, Shc binds the phosphorylated RTK (or other activated kinase) by a phosphotyrosine (pY) residue-containing site (bearing the consensus sequence NPXpY, where X is any amino acid 12 ) through its PTB domain. Recruitment to the activated receptor results in the phosphorylation of Shc at tyrosine residues within its CH1 domain that then provide a binding site for the adaptor protein Grb2. The phosphorylation of Shc also causes a conformational change that exposes its SH2 domain to interactions with phosphorylated downstream signaling proteins 15, 16 . The Shc-Grb2 complex activates the MAPK pathway through a sequence of events-involving the recruitment of Sos and upregulation of Ras and Raf-that ultimately results in the phosphorylation of Erk by Mek 17, 18 .
Erk plays a fundamental part in RTK-mediated intracellular signals controlling cell growth, differentiation and survival. It is also upregulated in many forms of cancer, including ovarian and prostate cancers and Hodgkin's disease [19] [20] [21] . Erk has two well-studied functionally and structurally similar isoforms, Erk1 and Erk2 (henceforth communally referred to as Erk), that act as the terminal kinase in the MAPK pathway. Phosphorylation of Erk by Mek is necessary and sufficient for the dissociation of the Erk-Mek complex 22 . Upon phosphorylation, Erk acts as a serine-threonine kinase on numerous substrate proteins [23] [24] [25] and/or translocates to the nucleus to stimulate the transcription of specific genes 18, 26 . Prolonged Erk phosphorylation results in cell proliferation 27, 28 . Erk can also regulate the MAPK pathway through negative feedback inhibition. For example, Erk2 can hyperphosphorylate Raf1 and Sos, inactivating them and resulting in the downregulation of the signaling cascade 29 .
Here we describe the mechanism by which direct interaction between Shc and Erk restrains Erk's activity in the absence of growth-factor stimuli. This interaction functions to prevent the a r t i c l e s phosphorylation-dependent activation of Erk. The binding sites identified in this study-located on the PTB domain of Shc and the N-terminal lobe of Erk-have not previously been implicated in protein-protein interactions, to our knowledge. Upon extracellular stimulation, recruitment of Shc-Erk to phosphorylated RTKs through Shc's PTB domain causes a conformational change within Shc that results in the release of Erk from the complex, allowing it to play its activating part in the MAPK signal transduction pathway. To confirm the role of Shc in regulating Erk signaling, Caenorhabditis elegans was used to demonstrate that the absence of Shc has a clear upregulatory effect on Erk activity in vivo. Thus, Shc is revealed as a key negative regulator of MAPK signaling in nonstimulated cells that becomes a positive regulator upon binding activated RTKs, both through the release of Erk and the recruitment of downstream effector proteins to the receptor complex. In the context of constitutively upregulated RTKs, the loss of Shc regulation of Erk could be a contributing factor in exacerbating oncogenic phenotypes.
RESULTS

Shc directly binds Erk
As part of a broader investigation into the multiple-proteinbinding capability of the adaptor protein, we investigated whether Shc and Erk interact in mammalian cells. We immunoprecipitated Shc in three different cell lines and immunoblotted for Erk. In serumstarved NIH3T3, MKN28 and PC12 cells, we were able to observe an endogenous complex between Shc and Erk (Fig. 1) . Stimulation of the epidermal growth factor receptor (EGFR) by EGF reduced the association of Shc with Erk in all three cell lines (Fig. 1) . Because Shc is a known binding partner for EGFR upon growth-factor stimulation, it appeared that the activated, phosphorylated receptor might directly disrupt the interaction between Erk and Shc. In a reciprocal experiment, GST-tagged Erk immobilized on glutathione-agarose beads was incubated with HEK293T lysates and immunoblotted for endogenous Shc. The formation of the Shc-Erk complex was again apparent, and it dissociated upon stimulation by EGFR (Fig. 1d) . To characterize this interaction better, we quantified the binding affinity between Shc and Erk in vitro, using isothermal titration calorimetry (ITC). Both proteins were expressed in Escherichia coli, and Erk was titrated into Shc. Shc and Erk form a high-affinity 1:1 complex (equilibrium dissociation constant K d = 0.9 µM; Fig. 1f and Supplementary Table 1) .
Shc-Erk interaction occurs through unique binding sites
We next sought to characterize the molecular basis for the interaction between Shc and Erk. To date, the CH1 domain has been shown to form complexes only once Shc is phosphorylated 15, 30 . As a result, we hypothesized that the constitutive binding site for Erk on Shc would be found in either the PTB domain (ShcPTB) or the SH2 domain (ShcSH2). To test this, GST pulldowns from HEK293T or PC12 cell extracts were carried out using GST-ShcPTB and GST-ShcSH2 fusion proteins. The results of those experiments indicated that the ShcPTB, but not the ShcSH2, interacts with Erk (Fig. 2a,b) . The direct interaction between ShcPTB and Erk was further demonstrated by using an in vitro fluorescence resonance energy transfer (FRET)-based method. ShcPTB and full-length Erk were recombinantly expressed as N-terminal fusions with the blue and green fluorescent proteins, respectively (BFP-Shc and GFP-Erk). The addition of increasing concentrations of GFP-Erk to BFP-ShcPTB resulted in increased FRET acceptor emission at 510 nm and decreased FRET donor emission at 480 nm, owing to excitation of the GFP acceptor fluorophore by the proximal BFP donor (Fig. 2c) . This spectroscopic assay provides strong evidence for the interaction of ShcPTB with Erk. This interaction was confirmed by ITC (K d = 9.5 µM; Fig. 2d and Supplementary Table 1 ). The affinity of the ShcPTB interaction with Erk was about an order of magnitude weaker than with the full-length Shc protein (Fig. 1f) . The intact protein therefore appears to stabilize the interaction of the PTB domain with Erk.
Small-angle X-ray scattering (SAXS), which allows determination of an ab initio low-resolution volume representation of proteins in solution, was used to provide a model for the molecular juxtaposition of ShcPTB and Erk in the complex. The SAXS models obtained had a volume and shape compatible with a compact 1:1 complex of Erk and ShcPTB ( Fig. 3a and Supplementary Fig. 1 ). Best-scored SAXS docking models placed the atomic structure of ShcPTB (PDB 1SHC) onto the N-terminal lobe of Erk (PDB 1TVO). These docking models fitted well to the ab initio SAXS reconstruction ( Fig. 3a and Supplementary Fig. 1 ). This structural analysis suggested that a long loop within ShcPTB (RRRKPCSRPLS, residues 97-107; henceforth referred to as Shc3R) contacts Erk. However the resolution obtained from SAXS was not sufficient to unambiguously determine the 
Physiological role of the Shc-Erk complex
Having demonstrated the existence of a Shc-Erk complex in nonstimulated cells and identified the binding sites on the respective proteins, we next investigated the physiological relevance of this interaction. To test whether the Shc-Erk complex affects Erk phosphorylation, we established stable HEK293T cell lines that overexpress wild-type Shc (Shc WT ) or the mutant Shc R98Q (in which Shc binding to Erk is compromised). The amount of phosphorylated Erk (pErk) in the cell reports on the ability of the Shc-Erk complex to modulate kinase and/or phosphatase activity toward Erk. Under serum-starved conditions, the amount of pErk was decreased by overexpression of Shc WT but not Shc R98Q (Fig. 4a) .
The conclusion that complex formation is important for the ability of Shc to suppress Erk phosphorylation is further supported by similar experiments carried out in HEK293T cells that stably express the Erk D20A D100A mutant in which the Shc-Erk interaction is also abrogated. Accordingly, the level of phosphorylation was greater in the Erk D20A D100A mutant compared to wild-type Erk (Erk WT )-expressing cells (Fig. 4b ). These data demonstrate that the ability of Shc to prevent Erk phosphorylation in unstimulated cells is mediated by direct interaction between the two proteins. Additional validation was obtained by depleting endogenous Shc from MCF7 cells by short hairpin RNA (shRNA). In agreement with the above observations (Fig. 3d) , the level of Erk phosphorylation was increased when the Shc-Erk complex was disrupted by knocking down endogenous Shc (Fig. 4c) . Because activated Erk translocates into the nucleus, we performed nuclear extraction assays to assess the accumulation of Erk in the nucleus following Shc knockdown. An increased amount of Erk was present in the nuclear fraction when endogenous Shc was depleted from MCF7 cells (Fig. 4d) . This is again consistent with Erk becoming phosphorylated and translocating to the nucleus in the absence of interaction with Shc. We also demonstrated that a greater amount of pErk was localized to the nucleus in the context of the Shc-Erk interaction-disrupting mutant Erk D20A D100A compared to Erk WT (Supplementary Fig. 2 ).
Activated Erk phosphorylates several proteins, including p90 RSK and Elk, which leads to the increased transcription of genes under the orientation of ShcPTB on Erk. We therefore used mutational analysis and binding assays with ShcPTB peptides to determine the orientation of ShcPTB toward its Erk-binding site. On the basis of all our structural, biophysical and functional data, a most likely molecular model of the interaction between Erk and the Shc3R sequence was produced by manually placing an atomic model of the Shc3R peptide in the experimentally determined binding site on Erk. This model was then energy minimized with Refmac5 (ref. 31) (Fig. 3b) . According to this model, the interaction of Erk with Shc appeared to be mediated through a previously unidentified binding site that is distal to both the canonical phosphotyrosine-and phospholipid-binding sites on ShcPTB 13, 32 .
To validate this model, a peptide based on the Shc3R sequence was synthesized and tested for binding to full-length Erk. According to ITC, the Shc3R binds Erk with a K d of 5.7 µM (Fig. 3c and  Supplementary Table 1) . The model predicted that Arg98 in ShcPTB would play a major part in the interaction with Erk (Fig. 3b) . To test the involvement of Arg98 in Erk binding, this residue was mutated to glutamine (ShcPTB R98Q ). Two control Shc variants were also generated: a key residue in a potential consensus Erk substrate-binding site, Trp24, was mutated to alanine (ShcPTB W24A ), and Arg175, a critical residue in the phosphotyrosine-binding pocket recognized by RTKs, was mutated to glutamine (ShcPTB R175Q ). ShcPTB R98Q was unable to pull down endogenous Erk from HEK293T cell lysates (Fig. 3d) , which confirmed that the amino acid sequence on ShcPTB required for binding includes the sequence incorporated in Shc3R (Fig. 3b) . The two other point mutants, ShcPTB W24A and ShcPTB R175Q , retained the ability to interact with Erk, which suggests that the interaction site for Erk on Shc does not include sites bound by previously reported Shc-binding proteins.
The region of Erk involved in binding Shc also represents a new site of interaction for this kinase 33 . To confirm the location of the binding site on the N-terminal lobe of Erk, two aspartic acid residues that were predicted to bind Shc3R in our model (Fig. 3b) , Asp20 and Asp100, were simultaneously mutated to alanines (Erk D20A D100A ). This Erk mutant was unable to pull down Shc from HEK293T cell lysate (Fig. 3d) , which confirmed the binding-site location. npg a r t i c l e s control of the promoter serum response element (SRE) 34 . We therefore investigated whether interaction with Shc affects the transcriptionstimulatory function of Erk in nonstimulated cells by using a luciferase reporter assay system. HEK293T cells stably overexpressing RFP-tagged wild-type ShcPTB (ShcPTB WT ) or ShcPTB R98Q were transfected with plasmids containing the firefly luciferase gene under SRE control. Plasmids containing the Renilla luciferase gene under the HSV thymidine kinase promoter were also simultaneously transfected to serve as internal controls. In the nonstimulated state, cells overexpressing ShcPTB R98Q exhibited an approximately two-fold-higher luciferase activity as compared with the ShcPTB WT -overexpressing cells (Fig. 4e) . This suggests that in the absence of interaction with Shc, Erk translocates to the nucleus and stimulates transcription in response to background MAPK activity.
Shc regulates Erk activation in C. elegans
Having discovered a constitutive interaction between Shc and Erk and demonstrated its physiological relevance in mammalian cells, we wanted to confirm these observations in an in vivo context. Because there are multiple Shc isoforms in mammalian model systems, we turned to the simple genetic model provided by C. elegans to assess the importance of the Shc-Erk interaction during development. C. elegans has single genes encoding Ras (let-60), Raf (lin-45), Mek (mek-2) and Erk (mpk-1). This signaling pathway is conserved across evolution, and the amino acid sequence and structure of C. elegans Erk and human Erk2 are highly conserved (the amino acid sequence identity and similarity in the Shc-binding region are 52% and 81%, respectively; Supplementary Fig. 3 ). The sequence of C. elegans Shc (shc-1) is conserved with human Shc, particularly within the PTB domain (Supplementary Fig. 3 ). Using germline development as a tissue context, we investigated the role of the ShcPTB R98Q mutation on Erk signaling and activation in C. elegans. The wild-type C. elegans germ line exhibits a stereotypical biphasic mode of Erk activation (Fig. 5) .
Erk is first activated, as visualized by an antibody that recognizes the active dually phosphorylated form of Erk (active Erk, red in Fig. 5a ).
The two zones of activation are labeled Zone 1 and 2 (Fig. 5a) . The downregulation of Erk in the loop region is critical for normal meiotic progression of oogenic germ cells 24, 35 . Worms that lack shc-1 (shc-1(0)) exhibit a continuous Erk activation pattern in the germ line ( Fig. 5c ) and lose the characteristic bimodal pattern of activation and higher nuclear accumulation in oocytes (Fig. 5c, arrowheads) . This higher ectopic and continuous activation of Erk disrupts the bimodal pattern of Erk activation and is similar to that observed in a ras gain-of-function mutant, let-60 ga89(Ras V12G ) (Fig. 5b) . Continuous activation of Erk causes the formation of multiple small oocytes in these germ lines as they age 36 , the phenotype that causes sterility and growth defects in these differentiated meiotic cells ( Supplementary  Fig. 4) . Because the shc-1(0) mutant has a similar Erk activation phenotype to a ras gain-of-function mutant, it suggests that C. elegans Shc-1, much like its vertebrate homolog, can negatively regulate Erk activation and phosphorylation (Fig. 5a,b and Supplementary Fig. 3) .
To test the function of the Shc-Erk complex in vivo, we transformed wild-type human Shc (hShc WT ) into the shc-1(0) worms. The hShc constructs included a C-terminal GFP tag, which was previously shown to have negligible effect on protein stability or function 30 . We found that hShc WT -GFP suppressed ectopic nuclear accumulation of phosphorylated Erk in the shc-1(0) background and restored the normal bimodal pattern of Erk activation typically observed in the C. elegans germ line 24, 35, 36 (Fig. 5d) . We generated five independent lines and characterized the most stable one (denoted visIs18) in more detail. We found that the accumulation of pErk in all shc-1(0) hShc WT lines was restored to a wild-type pattern (Fig. 5d) . When we compared the levels of pErk accumulation between shc-1(0) hShc WT , shc-1(0) and wild-type worms, we found (after quantification using Image J) 
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that the overall accumulation levels were ~40% lower in the transformed vizIs18 line compared to wild type (dotted lines in Fig. 5d ; Supplementary Fig. 4) . The difference probably resulted from a slightly higher affinity for Erk or greater cellular concentration of hShc WT in vizIs18 compared to those of shc-1 worms. To confirm that hShc WT is capable of binding the C. elegans Erk homolog MPK-1, we demonstrated that GST-tagged MPK-1 immobilized on agarose beads was able to pull down Shc overexpressed in HEK293T cells (Supplementary Fig. 4e ).
To directly test the impact of Shc binding on Erk function, hShc R98Q was expressed on the shc-1(0) background. We obtained five independent lines that had hShc R98Q -GFP expression levels similar to those of the hShc WT -GFP line (Fig. 5d,e) . In one of these lines, vizIs19, we found that, unlike hShc WT , hShc R98Q did not suppress the continuous pattern of Erk activation (Fig. 5e) and that it phenotypically resembled a let-60 ras gain-of-function mutant (at the permissive temperature; Fig. 5b) , consistent with the compromised binding of Shc R98Q that results in the upregulation of Erk activity in mammalian cells. Morphologically, these worms are sluggish, cannot tolerate osmotic pressures and often produce the small-oocyte phenotype that results in sterility, all of which are ras gain-offunction-like phenotypes. This suggests that Shc negatively regulates Erk function by sequestering Erk away from the canonical Ras-RafMek MAPK pathway in those worms. In the absence of the Shc-Erk complex, the pathway is activated, resulting in excessive Erk phosphorylation. The observations made in C. elegans are therefore consistent with the observations made in mammalian cells.
Phosphopeptide binding promotes Erk dissociation from Shc
The Shc-Erk complex forms in the absence of extracellular stimulation. Because the abundance of the endogenous Shc-Erk complex is reduced upon growth-factor stimulation (Fig. 1) Table 1) .
Previously reported NMR spectroscopic structural data on ShcPTB indicated that the apo form of the domain is partially disordered 37 .
Regions associated with the binding of a tyrosine-phosphorylated peptide (pTrkA, derived from the TrkA nerve growth-factor receptor, a physiological ligand for Shc) that are distal from the Erk-binding site identified here are particularly dynamic. The binding of pTrkA to Shc results in reorganization of the Erk-binding site through local folding events that appear to trigger a conformational switch between the free and complex states 32, 37 . This conformational switch is exemplified by previously observed NMR chemical-shift changes (∆δ) between apo and peptide-bound ShcPTB 37 . Considering the possible existence of an inducible conformational change between TrkA-and Erk-binding sites on ShcPTB, it is notable that large ∆δ values were observed not only in the β2-α2 loop region (residues 61-70, in direct contact with pTrkA) but also in a sequence encompassing helix α2 (residues 72-87). Although not in direct contact with pTrkA, residues 75, 76, 78, 79 and 80 within ShcPTB helix α2 displayed the largest ∆δ of all residues 37 . Gln76, Arg79 and Glu80 point toward the α2-β3 loop that contains the Erk-binding Shc3R motif (Supplementary Fig. 1c) .
Residues from the α2-β3 loop region also experience significant ∆δ, especially Ser103, which faces Gln76, Arg79 and Glu80 of the α2-β3 loop 37 . On the basis of these data, we speculated that the observed disruption of the Shc-Erk complex by pTrkA results from an allosteric mechanism in which pTrkA binding introduces structural changes onto the β2-α2 loop that are then propagated by α2 residues to the Erk-binding motif.
To confirm this allosteric model, we tested whether the presence of a known phosphotyrosine-peptide ligand could disrupt the Shc-Erk complex. In an ITC experiment, ShcPTB was titrated into Erk in the presence of pTrkA. No binding between Shc and Erk was observed under those conditions (Supplementary Fig. 1d ), which indicates that pTrkA prevents formation of the Shc-Erk complex, presumably by altering the conformation of Shc. Dissociation of the Shc-Erk complex through phosphotyrosine-ligand binding was confirmed with an in vitro FRET-based approach using either recombinant full-length phosphorylated cytoplasmic domain of EGFR (pEGFR cyto ; Fig. 6a ) or pTrkA (Fig. 6b) . The ShcPTB domain was C-terminally tagged with BFP, and Erk was N-terminally tagged with GFP. The interaction of ShcPTB and Erk results in the fusion-protein fluorophores being brought into proximity, resulting in energy transfer between the BFP (donor) and GFP (acceptor). Addition of either the pTrkA peptide or pEGFR cyto resulted in a reduction in the magnitude of the energy transfer. For example, a gradual change in FRET (that is, an increase in donor-emission fluorescence with a concomitant decrease in acceptor-emission fluorescence) was observed as the concentration of pEGFR cyto increased (Fig. 6a) . This confirmed that the binding of ligand to the known phosphotyrosine-binding site of ShcPTB results in the dissociation of the Shc-Erk complex.
In addition, we demonstrated that the Shc-Erk interaction was inhibited by tyrosine-phosphorylated ligand binding in a pulldown experiment in a cellular context (Fig. 6c) . HEK293T cells overexpressing streptavidin-tagged Shc WT were starved overnight and the exogenous Shc precipitated by Strep-Tactin agarose beads and washed under nonstringent conditions before pTrkA or pEGFR peptides were incubated with the precipitated material. In the presence of these ligands, the interaction between Erk and Shc was abrogated, as evidenced by the absence of Erk from the eluted fractions. These data support a mechanism for phosphotyrosine ligand-stimulated dissociation of Shc from Erk (Supplementary Fig. 1e ).
DISCUSSION
Significant basal kinase activity prevails in cells in the absence of extracellular stimulation 38 . This requires that control mechanisms be [39] [40] [41] . Erk also has several cognate sites for binding partners 33, 42 . However, the ShcPTB-Erk interaction maps to sites unique on the surfaces of both Shc and Erk, which suggests a specialized function. The previously reported site closest to the one we identified for the ShcPTB-Erk interaction involves the yeast scaffold protein Ste5 binding a site on the N-terminal lobe of Fus3, an Erk homolog 43 . However, the corresponding site on the N-terminal lobe of human Erk is occluded by Erk's own N terminus and hence prevents ligand binding. Alignment of Shc sequences from vertebrates and invertebrates indicates that the binding site for Erk is conserved 40 .
That there are, to our knowledge, no reported competing interactions for this site suggests that the maintenance of the Shc-Erk complex is important for cellular homeostasis and is probably disrupted only in the context of signaling. Thus, control of Erk by Shc is preserved in the presence of other potential functional interactions of these proteins. Shc's functioning as an adaptor protein in stimulated cells by forming a docking platform for enzymes involved in receptor-mediated signaling is well established. The involvement of Shc in signal transduction in response to growth-factor stimulation is contrasted by its function in the absence of cellular stimulation. One notable interaction in this context is the binding of Shc to protein phosphatase 2 (PP2) under basal conditions 44 . Similarly to Erk, PP2 is released upon stimulation by EGF or insulin-like growth factor 1. Furthermore, the Shc-PP2 complex is believed to negatively regulate growth-factor signaling. This is because the presence of PP2 prevents phosphorylation of Shc and the subsequent recruitment of Grb2. Thus, although the result of the dissociation of the Shc-PP2 complex is similar to that of the Shc-Erk complex, the mechanism of regulating MAPK signaling is entirely different.
Erk activity has also been shown to be regulated by cellular proteins other than Shc. For example, the phosphoprotein enriched in astrocytes 15 (Pea-15) protein has been demonstrated to regulate the subcellular localization of Erk and to control the outcomes of MAPK signaling 45, 46 . Pea-15 binds Erk regardless of its phosphorylation status, and as a result cells depleted of Pea-15 show increased levels of Erk in the nucleus. In addition, the similar expression to FGF (Sef ) protein also regulates Erk cellular localization. This is achieved through Sef 's binding the activated forms of Mek and preventing the dissociation of Erk from Mek 47 . Again, knockdown of Sef results in nuclear accumulation of Erk in stimulated cells. Notably, although Pea-15 and Sef exert control over the spatial distribution of Erk (the latter in stimulated cells only), neither is involved in induction of MAPK signaling as shown here for Shc. Thus, Shc is unique in exerting a dual influence on Erk activation and its downstream response.
ShcPTB binds a distinct set of activated growth-factor receptors including TrkA, EGFR, ErbB2 and ErbB3. The resulting tyrosine phosphorylation of Shc promotes signal transduction through the MAPK pathway 15 . However, this work highlights that the recruitment to an appropriate RTK also results in the release of Erk from Shc, which increases the cellular concentrations of free Erk able to increase MAPK signaling and downstream gene transcription. Shc therefore has a central role in modulating MAPK signaling through two distinct mechanisms and could be fundamental in controlling Erk activationsensitive cellular outcomes of MAPK-mediated signal transduction 25 . In the context of oncogenic activating mutations of receptors, there would be increased recruitment of Shc to phosphotyrosine-containing binding sites and hence elevated levels of free Erk. This would have an effect on the amplification of MAPK signal transduction and hence increase proliferative potential.
Erk has multiple roles in the acquisition of complex malignant phenotypes, hence downregulation of Erk activity is expected to produce antiproliferative, antimetastatic and/or antiangiogenic effects in tumor cells. It has already been demonstrated that reducing the cellular concentration of Erk by RNA interference leads to the suppression of tumor cell proliferation in ovarian cancer cells 19 . Small-molecule inhibition of Shc-RTK interaction that preserves Shc-Erk binding could have a similar effect by maintaining the engagement of the Shc-Erk complex.
METhODS
Methods and any associated references are available in the online version of the paper.
